Physician Assistant Title Change Gains Traction Nationwide
To date,
Informed by rigorous and substantial research by independent experts, the American Academy of Physician Associates (AAPA) decided in 2021 to change the profession's title. In the years since, AAPA, its affiliate organizations, and PA programs have been working to update the profession's title to ensure patients understand the role of PAs in healthcare delivery and the high-quality care PAs provide.
Several other states continue to push for title change efforts, including
"The term 'assistant' no longer reflects our role in healthcare or our partnerships with physicians," said
Updating the profession's title ensures that terminology keeps pace with the profession and represents a broader shift in how healthcare professionals are recognized and valued. As more states consider similar legislation and programs to pursue change, the momentum is growing.
To learn more about efforts to advance title change for the PA profession, visit AAPA's Title Change page.
About the American Academy of Physician Associates (AAPA)
AAPA is the national professional organization for all physician associates/assistants (PAs). PAs are licensed clinicians who practice medicine in every specialty and setting. Trusted, rigorously educated and trained healthcare professionals, PAs are dedicated to expanding access to care and transforming health and wellness through patient-centered, team-based medical practice. Learn more about the profession at aapa.org and engage through Facebook, LinkedIn,Instagram, and X.
View original content to download multimedia:https://www.prnewswire.com/news-releases/physician-assistant-title-change-gains-traction-nationwide-302595341.html
SOURCE American Academy of Physician Associates
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Everlight Wins 2026 Madison People's Choice Award
- Best Crypto Presales Before the Fed Decision: 7 Early Plays While BTC Battles $77K
- Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share